Management of fluoroquinolone resistance in Pseudomonas aeruginosa - Outcome of monitored use in a referral hospital

L. R. Peterson*, M. Postelnick, T. L. Pozdol, B. Reisberg, G. A. Noskin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


We evaluated a strategy designed to improve useful activity of ciprofloxacin against Pseudomonas aeruginosa. Following changes in antimicrobial agent use made by the institutional Pharmacy and Therapeutic Drug Committee, monthly drug usage and microbial susceptibility records from June 1992 through October l995 were reviewed. From July 1992 through October 1992 (Period 1), ciprofloxacin and ofloxacin usage represented 95 and 5% of total quinolone doses; from December 1992 to March 1993 (Period 2), ciprofloxacin represented 19%; from July 1993 to October 1993 (Period 3), ciprofloxacin usage represented 85%; from July 1994 to October 1994 (Period 4), ciprofloxacin represented 95%; and from July 1995 to October 1995 (Period 5), ciprofloxacin and ofloxacin respectively represented 98 and 2% of total quinolone doses. Comparison of the anti-pseudomonal activity of the two fluoroquinolones to ofloxacin use, ciprofloxacin use and total quinolone use during the entire observational period showed the highest (negative) correlation with ofloxacin use versus ofloxacin activity (y=-15.04x+1367.99, r2=0.06, w=0.126). Increased use of quinolones plus a change to primarily ofloxacin usage appeared to adversely affect the activity of both ofloxacin and ciprofloxacin against P. aeruginosa. Copyright (C) 1998 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)207-214
Number of pages8
JournalInternational Journal of Antimicrobial Agents
Issue number3
StatePublished - Aug 1998


  • Antimicrobial drug resistance
  • Fluoroquinolone
  • Formulary management
  • Pseudomonas aeruginosa

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Management of fluoroquinolone resistance in Pseudomonas aeruginosa - Outcome of monitored use in a referral hospital'. Together they form a unique fingerprint.

Cite this